ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 03/25/24

- Expanded Access Program initiated to make investigational plozasiran available to patients with familial chylomicronemia syndrome - New SHASTA-2 Phase 2 clinical data in patients with severe hypertriglyceridemia to be presented at ACC.24 Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR...

2024-03-20 18:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-18 17:45:43 ET More on Inventiva Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause Inventiva resumes Phase 3 study for NASH drug, stock up 6% Inventiva drops after adverse event in Phase 3 trial for NASH drug Seeking Alphaȁ...

2024-03-15 08:19:55 ET More on Madrigal Pharmaceuticals Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's...

2024-03-14 15:45:17 ET More on Madrigal Pharmaceuticals Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's...

2024-03-14 10:42:03 ET More on Madrigal Pharma Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potentia...

2024-03-13 13:29:04 ET More on Madrigal Pharmaceuticals Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's...

2024-03-13 08:00:58 ET Ionis Pharmaceuticals ( NASDAQ: IONS ) shares rose in early trading on Wednesday after the company reported positive results from a mid-stage trial of its investigational drug to treat a type of fatty liver disease.... Read the full article on S...

2024-03-10 15:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

- Preclinical data show ARO-DM1 reduces muscular DMPK expression and corrects spliceopathies, which could lead to improved muscle strength and function Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a double-blinded, place...